MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/cco-23-153

Медицинская библиотека · Chinese clinical oncology · 2024

A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment.

Hirano Satoshi, Takahashi Hidekazu, Nakamura Sukeyuki, Matsuda Kousei, Ishikawa Rintaro, Tamura Kei, Shikano Kohei, Fujita Tetsuo, Amano Hiroyuki, Nakamura Makoto

Клинический случайСтатьяПеревод в очереди

Аннотация

BACKGROUND

Immune checkpoint inhibitors (ICIs) have become key agents in the treatment of non-small cell lung cancer worldwide. However, immune-related adverse events (irAEs) must be addressed to maximize the efficacy of ICIs. Mycobacterium tuberculosis (Mtb) infection is considered as a type of irAE associated with ICIs, but the underlying mechanism is not completely understood. Here, we present a case of pulmonary tuberculosis (TB) that developed during administration of nivolumab and ipilimumab for pulmonary adenocarcinoma that recurred just 2 months after completion of anti-TB treatment.

CASE DESCRIPTION: A 67-year-old man with lung adenocarcinoma was referred to our hospital for chemotherapy. He was a former smoker and had been diagnosed with stage IVA (cT4N1M1a) lung adenocarcinoma. Interferon-gamma release assay (IGRA) yielded positive results at the start of treatment. One month after initiating treatment with nivolumab and ipilimumab, he presented with productive cough and Mtb complex was cultured from sputum samples. Two months after completing anti-TB treatment, recurrence of TB was observed. The series of strains were found to be identical.

CONCLUSIONS

This represents the first report of pulmonary TB that developed during nivolumab and ipilimumab treatment, and recurred 2 months after completing anti-TB treatment. Physicians should be mindful of the potential for TB recurrence following the use of ICIs, particularly in patients showing positive results from IGRA.

Для цитирования: Hirano Satoshi, Takahashi Hidekazu, Nakamura Sukeyuki, Matsuda Kousei, Ishikawa Rintaro, Tamura Kei, Shikano Kohei, Fujita Tetsuo, Amano Hiroyuki, Nakamura Makoto. A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment.. Chinese clinical oncology. 2024. DOI: 10.21037/cco-23-153.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.